On Thursday, Shares of Hain Celestial Group Inc (NASDAQ:HAIN), gained 0.50% to $52.17. The stock attained the volume of 1.07 million shares.
Perrigo Company plc (PRGO), declared that The Hain Celestial Group, Inc. (HAIN) through its Earth’s Best® brand, has begun to sell organic infant formula in Hong Kong and China, through Hutchison Hain Organic Holdings Limited, Hain Celestial’s joint venture with Hutchison China MediTech Limited (LSE AIM: HCM). Chi-Med’s majority owner, CK Hutchison Holdings Limited, is one of the largest companies in Asia, with a rich history and core retail business. According to Euromonitor data, sales of formula in China exceeded $16.5 billion in 2014.
Perrigo, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, is a leading U.S. manufacturer and supplier of infant formula. Perrigo produces infant formulas for world markets in FDA-inspected, ISO 9001:2008-certified, cGMP facilities based in the United States. Hain Celestial is a leading organic and natural products company with operations in North American, Europe and India.
Perrigo’s Chairman, President and CEO, Joseph C. Papa stated, “We are excited to declare the entry of Hain Celestial’s Earth’s Best Organic® Infant Formula into the Hong Kong and Chinese market. Infant formula is a premium product in China, and we believe Earth’s Best® organic formula will be an attractive offering to families in Hong Kong and Mainland China.”
The Hain Celestial Group, Inc. manufactures, markets, distributes, and sells organic and natural products in the United States, the United Kingdom, Canada, and Europe.
Shares of Insmed Incorporated (NASDAQ:INSM), dropped -7.46% to $17.12, during its last trading session.
Insmed Incorporated (INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, stated new nontuberculous mycobacteria (NTM) lung disease information will be presented at the Infectious Disease Week 2015 (IDWeek) meeting taking place in San Diego, California from October 7-11. IDWeek is the combined annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, HIV Medicine Association, and Pediatric Infectious Diseases Society.
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers an anti-infective directly to the site of serious lung infections.
Finally, Alkermes Plc (NASDAQ:ALKS), ended its last trade with -0.13% loss, and closed at $59.90.
Alkermes plc (ALKS) declared that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA right away.
ARISTADA’s features, counting a range of dose strengths and dosing interval options, are designed to address the individual needs of patients and challenges in the treatment of schizophrenia. As a long-acting injectable medicine, ARISTADA provides patients, clinicians and families the certainty that patients receive medication for this serious brain disorder. Long-acting injectable antipsychotics provide patients with blood concentrations of active drug that remain within a therapeutic range for an extended period of time1 and assist healthcare providers to track patient adherence.2
The FDA approval of ARISTADA was based on a proven safety and efficacy profile, counting data from a randomized, double-blind, placebo-controlled, phase 3 study in 623 patients with schizophrenia. Data from that trial showed that multiple dose strengths of ARISTADA met the primary endpoint with statistically noteworthy and clinically meaningful reductions in Positive and Negative Syndrome Scale (PANSS) total scores at Week 12, met the key secondary endpoint and demonstrated noteworthy improvements in schizophrenia symptoms as compared to placebo. The most common adverse events in the study were insomnia, akathisia and headache. The results of the phase 3 study were published in June 2015 by The Journal of Clinical Psychiatry, a peer-reviewed medical journal.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.